Skip to main content
. 2022 Sep 1;14(17):4284. doi: 10.3390/cancers14174284

Figure 6.

Figure 6

Profiles associated with discontinuation due to AEs in patients with HCC treated with atezo/beva. Decision-tree algorithm for discontinuation due to AEs. The pie graphs indicate the percentage of no discontinuation due to AEs (white)/discontinuation due to AEs (black) in each group. HCC, hepatocellular carcinoma; atezo/beva, atezolizumab plus bevacizumab.